Drug Type Cell therapy |
Synonyms- |
Target- |
Mechanism Cell replacements |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 2 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Intermittent Claudication | Phase 2 | US | 05 Nov 2012 | |
Intermittent Claudication | Phase 2 | DE | 05 Nov 2012 | |
Intermittent Claudication | Phase 2 | IL | 05 Nov 2012 | |
Intermittent Claudication | Phase 2 | KR | 05 Nov 2012 | |
Peripheral Arterial Disease | Phase 2 | US | 05 Nov 2012 | |
Peripheral Arterial Disease | Phase 2 | DE | 05 Nov 2012 | |
Peripheral Arterial Disease | Phase 2 | IL | 05 Nov 2012 | |
Peripheral Arterial Disease | Phase 2 | KR | 05 Nov 2012 | |
Muscle injury | Phase 2 | DE | 01 Nov 2012 |
NCT04614025 (Biospace) Manual | Phase 2 | 23 | PLX-PAD | ejoluznxbz(havhohklnh) = tsumthfwvy krqmnfzkru (pjfbrbjdiz ) View more | Negative | 27 Dec 2021 | |
NCT04389450 (Biospace) Manual | Phase 2 | 66 | PLX-PAD | npjhkqhxqr(mjjaewlyae) = The Studies did not meet the primary efficacy endpoint of statistically significant improvement of VFD at 28 days hvoagsmjrq (mmcdiglzss ) | Negative | 27 Dec 2021 |